Summary
Schering-Plough Corporation's second quarter 2006 10-Q filing reveals a significant turnaround, with net income available to common shareholders of $237 million, a substantial improvement from a net loss of $70 million in the same period last year. This rebound is largely driven by the strong performance of the cholesterol franchise, particularly VYTORIN and ZETIA, which are marketed in partnership with Merck. Net sales for the quarter increased 11% year-over-year to $2.8 billion, reflecting growth across key prescription pharmaceutical products like REMICADE, NASONEX, and PEG-INTRON. Despite the positive financial momentum, the company is undertaking significant restructuring, announcing plans to close manufacturing facilities in Puerto Rico and New Jersey, resulting in approximately 1,100 job eliminations and associated special charges. The company also continues to navigate ongoing legal and regulatory matters, including investigations related to past sales and marketing practices, which have resulted in a $500 million liability reserve. Investors should note the continued dependence on the cholesterol franchise for profitability and the inherent risks associated with the pharmaceutical industry, including R&D failures and regulatory challenges.
Key Highlights
- 1Achieved significant profitability in Q2 2006 with $237 million in net income available to common shareholders, compared to a $70 million net loss in Q2 2005.
- 2Net sales grew 11% to $2.8 billion in Q2 2006, driven by strong performance in Prescription Pharmaceuticals, particularly REMICADE, NASONEX, and PEG-INTRON.
- 3The cholesterol franchise (VYTORIN and ZETIA), in partnership with Merck, is a primary driver of financial performance, contributing $355 million in equity income in Q2 2006.
- 4The company announced manufacturing restructuring plans, including facility closures in Puerto Rico and New Jersey, leading to approximately 1,100 job eliminations and associated special charges.
- 5Ongoing legal and regulatory challenges persist, notably the Massachusetts investigation for which the company has recorded a $500 million liability.
- 6Research and Development (R&D) spending increased by 22% to $539 million in Q2 2006, reflecting continued investment in the product pipeline.
- 7The company adopted SFAS 123R (Share-Based Payment) effective January 1, 2006, requiring recognition of compensation expense based on fair value of share-based awards.